Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Extends distribution and marketing agreement with EffRx Pharmaceuticals in Switzerland to include Efmody.
In October 2020, EffRx gained the exclusive rights to market and distribute Alkindi in Switzerland, and will now apply to Swissmedic for the registration of Efmody as treatment for adolescent and adult patients with the condition of congenital adrenal hyperplasia during the second half of 2022.
"We are pleased to deepen our relationship with EffRx to include the distribution and marketing of Efmody in Switzerland. We have been impressed by the progress EffRx has made with the regulatory approval and reimbursement of Alkindi and look forward to continuing to work with them as they prepare to submit an MAA to Swissmedic for Efmody," says Interim Chief Executive Officer Richard Bungay.
Current stock price: 14.29 pence
12-month change: down 79%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
